3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
26
Lymphoma, Non-Hodgkin
23
Lymphoma
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Myelodysplastic Syndromes
18
Hematologic Neoplasms
18
Melanoma
16
Neoplasm Metastasis
15
Lymphoma, B-Cell
14
Multiple Myeloma
12
Pancreatic Neoplasms
11
Hodgkin Disease
11
Stomach Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Breast Neoplasms
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Uterine Cervical Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Neoplasms, Plasma Cell
5
Kidney Neoplasms
5
Burkitt Lymphoma
5
Myeloproliferative Disorders
4
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Erlotinib Hydrochloride
4
pembrolizumab
3
aldesleukin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
Cyclophosphamide
2
Bevacizumab
2
veliparib
1
trametinib
1
spartalizumab
1
satraplatin
1
osimertinib
1
onartuzumab
1
nintedanib
1
methyl-4-fluoro-4-deoxyglucose
1
fludarabine phosphate
1
fludarabine
1
bemarituzumab
1
anlotinib
1
aflutinib
1
Taxes
1
Sorafenib
1
Sirolimus
1
Radiotherapy, Conformal
1
Radiosurgery
1
Pentostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma of Lung
×
fludarabine
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn